Ventria Bioscience的分公司InVitria 成立的目标是为生物技术行业提供**产品，以改善细胞培养和生物制造。InVitria通过允许客户从其基于细胞的过程中消除动物成分来实现这一点。拆除这些组件有助于提高一致性，**性和效率。InVitria的产品是在我们位于堪萨斯州Junction City的生产设施中生产的重组蛋白。这些产品在生命科学行业有很多用途，包括再生医学，细胞**，生物制造，疫苗，诊断和医疗设备。
诸如胎牛血清（FBS），牛和人血清白蛋白以及牛和人转铁蛋白的动物组分已经在许多生物过程中成为流行的成分，但是在二十世纪九十年代，科学家开始寻找**血清和其它动物产品的方法关注产品质量，**和动物管理。动物产品是不受欢迎的，因为它们具有传播感染性物质如朊病毒（疯牛病）和病毒（HIV）的风险。另外，动物组分和血液衍生产品是不确定的，导致批次间的高度差异。由于这些原因，美国食品和**管理局（FDA），欧洲药品管理局（EMA）和其他监管机构不鼓励使用这些动物成分。
“我喜欢与负责批准InVitria作为供应商的客户审计师合作。他们来自世界上一些*成功的生物制药和生命科学公司，所以他们的期望很高。我们的期望也很高，并导致成功的结果。“
InVitria与生物制药公司，优越大学，国家卫生研究院和**控制中心进行了多项研究合作，以加强我们的产品开发和发现新的产品机会。对于学术研究人员，InVitria通过BioShare计划提供支持。
InVitria –Performance. Defined.
InVitria, a division of Ventria Bioscience, was founded with the goal of providing the biotechnology industry with innovative products to improve cell culture and biomanufacturing. InVitria does this by allowing customers to eliminate animal components from their cell-based processes. Removing these components helps improve consistency, safety and efficiency. InVitria’s products are recombinant proteins that are manufactured in our manufacturing facility in Junction City, Kansas. These products have many uses across the life science industry including in regenerative medicine, cellular therapy, biomanufacturing, vaccines, diagnostics and medical devices.
Animal-components such as fetal bovine serum (FBS), bovine and human serum albumin, and bovine and human transferrin have been popular ingredients in many biological processes, but in the 1990’s scientists began searching for ways to remove serum and other animal products due to concerns about product quality, safety and animal stewardship. Animal products are undesirable because they pose a risk of transmitting infectious agents such as prions (Mad Cow Disease) and virus (HIV). In addition, animal components and blood derived products are undefined leading to high batch-to-batch variation. For these reasons, the Food and Drug Administration (FDA), European Medicines Agency (EMA) and other regulatory bodies discourage use of these animal components.
To date, InVitria has developed and commercialized eight recombinant proteins and cell culture media supplements. InVitria’s product development team has an active program to expand this product line based on customer needs.
At InVitria, we are proud of our team and our partnerships.
InVitria’s team is committed to providing innovative solutions to the most pressing cell culture challenges today.
“Helping customers integrate these animal component free products to improve their processes and reach their commercial objectives is what excites me about InVitria”
– Steve Pettit, Ph.D. Director, Cell Culture
“I like working with our customer auditors who are responsible for approving InVitria as a vendor. They come from some of the most successful biopharmaceutical and life science companies in the world, so their expectations are high. Our expectations are also high and that leads to a successful outcome.”
– Pat Smith, Director, Quality
As a Division of Ventria Bioscience, InVitria has access to Ventria’s Board of Directors and their expertise and successful history. These leaders include:
-
a member of the National Academies of Science and 2003 Biotechnology Heritage Award Winner,
-
former Chairman and CEO of the largest plant biotechnology company in the world,
-
two founders of Chiron Corporation (now Novartis),
-
former President of Johnson & Johnson’s diagnostics business,
-
Chairman of PRA International, a leading clinical trial CRO,
-
the former President of millipore’s Bioscience Division, and
-
two General Partners of leading healthcare venture capital firms.
